Logo

American Heart Association

  13
  0


Final ID: MDP612

Outcomes of Percutaneous Coronary Interventions Following Transcatheter Aortic Valve Replacement: Insights from the National Cardiovascular Data Registry (NCDR) CathPCI Registry

Abstract Body (Do not enter title and authors here): Background: Although transcatheter aortic valve replacement (TAVR) devices can impair coronary access, there are limited real-world data on rates of percutaneous coronary intervention (PCI) and PCI outcomes in post-TAVR patients.
Research Question: How often do patients who undergo TAVR develop coronary events, and do they have different procedural characteristics or rates of adverse events when undergoing PCI compared to patients without a TAVR?
Methods: We used CMS claims data for the Medicare fee-for-service population to evaluate the incidence of PCI after TAVR between 2011-2017. Then, using data from the NCDR CathPCI Registry linked with Medicare claims, we compared procedural characteristics and PCI outcomes between patients with a history of TAVR vs. propensity-matched patients who did not have a history of TAVR.
Results: Of the 52,780 Medicare fee-for-service patients who underwent TAVR between 2011-2017, the incidence of acute myocardial infarction (AMI) was 10.6% and of PCI was 5.4% at five years. Among those patients, 5.6% had a PCI in the three months preceding their TAVR. After propensity-score matching, the procedural success rates for PCI were similar between patients with vs. without a history of TAVR. However, in the propensity-matched comparison, PCI in post-TAVR patients required greater fluoroscopic time (21.9 vs 17.7 mins, p<0.001) and was associated with a greater incidence of post-procedural stroke (0.8% vs 0.4%, p=0.02) and bleeding (5.1% vs 2.9%, p < 0.001). At three-year follow-up post-PCI, there were no differences in the rates of AMI between patients with vs. without a history of TAVR (HR: 1.22, 95% C.I.: 0.97, 1.54, p=0.08). However, patients with prior TAVR were more likely to have repeat PCI in the three years following their index procedure (HR: 1.38, 95% C.I.: 1.12, 1.73, p=0.003).
Conclusion: Among Medicare fee-for-service patients, one in 20 patients undergoing TAVR subsequently underwent PCI within 5 years. Although the rates of procedural success were similar, patients with a history of TAVR who underwent PCI had longer fluoroscopic times, more frequent in-hospital adverse events, and a higher likelihood of a repeat PCI compared with matched patients without a history of TAVR.
  • Lalani, Christina  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Kolte, Dhaval  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Cohen, David  ( Cardiovascular Research Foundation , New York , New York , United States )
  • Yeh, Robert  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Sharma, Ravi  ( Norton Healthcare , Louisville , Kentucky , United States )
  • Sevilla-cazes, Jonathan  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Kennedy, Kevin  ( St. Luke's Hospital , Kansas City , Missouri , United States )
  • Butala, Neel  ( University of Colorado , Aurora , Colorado , United States )
  • Secemsky, Eric  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Pinto, Duane  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Poulin, Marie-france  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Laham, Roger  ( Beth Israel Deaconess Medical Center , Boston , Massachusetts , United States )
  • Author Disclosures:
    Christina Lalani: DO NOT have relevant financial relationships | Dhaval Kolte: DO have relevant financial relationships ; Research Funding (PI or named investigator):NIH/NHLBI:Active (exists now) ; Research Funding (PI or named investigator):Edwards Lifesciences:Active (exists now) | David Cohen: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:Medtronic:Past (completed) ; Consultant:Edwards Lifesciences:Active (exists now) ; Consultant:Abbott:Active (exists now) ; Research Funding (PI or named investigator):IRhythm:Past (completed) ; Research Funding (PI or named investigator):Zoll Medical:Active (exists now) ; Research Funding (PI or named investigator):Corvia Medical:Active (exists now) ; Research Funding (PI or named investigator):Philips:Active (exists now) ; Research Funding (PI or named investigator):CathWorks:Active (exists now) ; Research Funding (PI or named investigator):Boston Scientific:Active (exists now) ; Research Funding (PI or named investigator):Edwards Lifesciences:Active (exists now) | Robert Yeh: DO have relevant financial relationships ; Consultant:abbott vascular :Active (exists now) ; Consultant:shiockwavw:Active (exists now) ; Consultant:cathworks:Active (exists now) ; Consultant:medronic:Active (exists now) ; Consultant:Boston scientific :Active (exists now) | Ravi Sharma: No Answer | Jonathan Sevilla-Cazes: No Answer | kevin kennedy: No Answer | Neel Butala: DO have relevant financial relationships ; Consultant:Boston Scientific:Past (completed) ; Ownership Interest:CatchBio:Active (exists now) ; Consultant:CatchBio:Active (exists now) ; Ownership Interest:HiLabs:Active (exists now) ; Consultant:HiLabs:Active (exists now) ; Consultant:Shockwave Medical:Past (completed) | Eric Secemsky: DO have relevant financial relationships ; Consultant:Abbott/CSI, BD, BMS, Boston Scientific, Cagent, Conavi, Cook, Cordis, Endovascular Engineering, Gore, InfraRedx, Medtronic, Philips, RapidAI, Rampart, Shockwave, Terumo, Thrombolex, VentureMed, Zoll:Active (exists now) | Duane Pinto: DO have relevant financial relationships ; Executive Role:Jenavalve:Active (exists now) ; Consultant:AriaCV:Active (exists now) ; Consultant:Magenta:Active (exists now) ; Consultant:Abbott:Active (exists now) | Marie-France Poulin: No Answer | Roger Laham: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

More abstracts on this topic:
30-day and one-year outcomes of patients with severe aortic stenosis after TAVI using Myval : A Meta-analysis

Hasabo Elfatih A., Sultan Sherif, Soliman Osama, A. Aboali Amira, Hemmeda Lina, Salah Alaa, Alrawa Salma S., Elgadi Ammar, Abdalmotalib Malaz, Yasir H Eissa Abdullatif, Mahmmoud Fadelallah Eljack Mohammed

A Novel RNA Interference Agent RN0191 Lowering Proprotein Convertase Subtilisin/Kexin Type 9, Low-density Lipoprotein Cholesterol and Other Lipid Biomarkers in Healthy Volunteers with Elevated LDL Cholesterol: A Randomized, Single-blind, Placebo-controlled, Phase 1 Trial

Wang Fangfang, Li Haiyan, Zeng Jie, Shi Yibin, Li Hongmei

More abstracts from these authors:
Changes in Contrast Volume among Patients Undergoing Percutaneous Coronary Intervention: a Report from NCDR CathPCI registry

Ikemura Nobuhiro, Chan Paul, Cohen David, Kennedy Kevin, Uzendu Anezi, Kohsaka Shun, Spertus John

Cannabis Legalization and Cardiovascular Hospitalizations: A Nationwide Difference-in-Differences Analysis

Slavin Samuel, Mahar Amy, Secemsky Eric, Yeh Robert, Mittleman Murray

You have to be authorized to contact abstract author. Please, Login
Not Available